Are you still recommending autologous stem cell transplantation (ASCT) for all eligible myeloma patients who achieve remission after induction with a quadruplet regimen?
Or can we omit it in older patients given efficacy of these regimens? Is transplant-eligibility still an important distinction up front given options for anti-CD38 regimens regardless?
Community PollStarted
Are you recommending up front auto-SCT (ASCT) for all eligible myeloma patients who achieve remission after induction with a quadruplet regimen?
56 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Wisconsin
Answered on
Our institution still recommends upfront autologous transplant for most fit patients. We appreciate the recent results from CEPHEUS and BENEFIT, but if we believe that achieving MRD negativity is important, the addition of autologous transplant improves the rate of MRD negativity, which ultimately s...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Dana-Farber Cancer Institute
Answered on
No. ASCT is a discussion process with the patients. The GRIFFIN and PERSEUS trials used Dara throughout induction, consolidation, and maintenance. The MRD- status deepened over the course of the treatment. The IFM-09 and DETERMINATION trials showed similar OS for patients with upfront vs delayed ASC...
Join for free or sign in to see the full answer